Daratumumab Or Darzalex Market Report 2026

Daratumumab Or Darzalex Market Overview

• The Daratumumab Or Darzalex market growth in the historic period has been driven by approval for multiple myeloma treatment, strong clinical outcomes targeting cd38 • Market expansion is supported by expansion of combination regimens, growing multiple myeloma prevalence • Growth Driver: Rising Incidence Of Bone Marrow Cancer Fuels Growth Of Daratumumab/Darzalex Market • Market Trend: Focus On Transmembrane Proteins And Enhanced Treatment Solutions • North America was the largest region in 2025.

What Is Covered Under Daratumumab Or Darzalex Market?

Daratumumab, or darzalex, refers to a monoclonal antibody used as a medication in the treatment of certain cancers, particularly multiple myelomas. It is designed to target and bind to CD38, a protein that is highly expressed on the surface of multiple myeloma cells, as well as other malignant and normal immune cells. The main types of drugs in daratumumab or darzalex are 100 mg injection and 400 mg injection. A 100 mg injection refers to a dose of a medication or therapeutic substance that is administered via injection, containing 100 milligrams (mg) of the active ingredient. These drugs can be distributed through pharmacies, hospitals, and other distribution channels for various applications, such as follicular lymphoma, mantle cell lymphoma, multiple myeloma, diffuse large B cell lymphoma, and others.

What Is The Daratumumab Or Darzalex Market Growth Forecast?

The daratumumab or darzalex market size is expected to see strong growth in the next few years. It will grow to $9024.5 million in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expansion of combination regimens, growing multiple myeloma prevalence, increased oncology investment, development of new indications, improved patient access programs. Major trends in the forecast period include rising adoption in multiple myeloma, combination use with other oncology drugs, expansion into earlier treatment lines, hospital based monoclonal antibody therapy, growing use in hematologic malignancies.

Global Daratumumab Or Darzalex Market Segmentation

1) By Drug Type: 100Mg Injection, 400Mg Injection 2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels 3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications

What Are The Drivers Of The Daratumumab Or Darzalex Market?

The rise in incidence of bone marrow cancer is expected to propel the growth of the daratumumab or darzalex market going forward. Bone marrow cancer refers to cancers that begin in the bone marrow, such as multiple myeloma and leukemia, where abnormal blood cell production disrupts normal body function. The rising incidence of bone marrow cancers can be attributed to an aging population, improved detection methods, and contributing factors such as environmental influences, lifestyle choices, and genetic predispositions. Daratumumab (Darzalex) helps in the treatment of multiple myeloma, a type of bone marrow cancer, by targeting and destroying abnormal plasma cells in the bone marrow. For instance, in January 2025, according to the American Cancer Society, a US-based non-profit organization, reported that in 2025 there will be around 3,770 new cases of primary bone and joint cancer (2,150 in men and 1,620 in women), along with approximately 2,190 deaths (1,240 in men and 950 in women). Therefore, the rise in incidence of bone marrow cancer is driving the growth of the daratumumab or darzalex industry. Rising adoption of biologics and targeted therapies is expected to propel the growth of the daratumumab or darzalex market going forward. Targeted therapies refer to a type of medical treatment that uses drugs or other substances to precisely identify and attack specific molecules involved in the growth and survival of cancer or other diseases. The adoption of biologics and targeted therapies is increasing due to the rising prevalence of chronic diseases and advancements in precision medicine, which enable more personalized, effective treatments. Daratumumab is utilized in targeted therapies due to its specific action on CD38, a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, rising adoption of biologics and targeted therapies is driving the growth of the daratumumab or darzalex industry.

Key Players In The Global Daratumumab Or Darzalex Market

Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.

Global Daratumumab Or Darzalex Market Trends and Insights

Major companies operating in the daratumumab or darzalex market are focusing on a shift in oncology treatments towards early intervention solutions such as combination therapies to enhance efficacy in treating multiple myeloma and other cancers. Combination therapies refer to treatment strategies that use two or more therapeutic agents with different mechanisms of action, often synergistically, to enhance efficacy, minimize resistance, and improve patient outcomes while potentially reducing adverse effects compared to monotherapy. For instance, in July 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in patients with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplant (ASCT). This new approval provides a quadruplet therapy option at initial diagnosis, potentially improving patient outcomes.

Regional Insights

North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Daratumumab Or Darzalex Market?

The daratumumab or darzalex market consists of sales of darzalex faspro, darzalex injection, dexamethasone, and pomalidomide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Daratumumab Or Darzalex Market Report 2026?

The daratumumab or darzalex market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the daratumumab or darzalex industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.